The FDA on November 19, 2025, granted traditional approval to IMDELLTRA® for adults with Extensive Stage Small Cell Lung Cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA® received accelerated approval for this indication in 2024. IMDELLTRA® is a product of Amgen Inc.
Bottom Ad
Advertisement
Subscribe
